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Abstract
Background: Mycobacteria, such as M. leprae and M. tuberculosis infect billions of humans. However, because of appropriate
immune responses and antibiotic therapy, overt mycobacterial diseases occur far less frequently. M. avium subspecies
paratuberculosis (MAP) causes Johne’s disease in ruminants, an affliction evocative of inflammatory bowel disease (IBD).
Several agents used to treat IBD (5-ASA, methotrexate, azathioprine and its metabolite 6-MP) have recently been shown to
be antiMAP antibiotics. We herein evaluate the prevalence of MAP DNA in healthy individuals and compare them with IBD
patients on antiMAP antibiotics.
Methods: We studied 100 healthy individuals (90 blood donors) and 246 patients with IBD. IS900 MAP DNA was identified
using a nested primer PCR in the buffy coat of blood. Positive signal was confirmed as MAP by DNA sequence analysis. PCR
positive results frequencies were compared according to medications used. Significance was accepted at p,0.05.
Results:47%(47/100)healthycontrolsand 16%(40/246)IBDpatientswere IS900positive(p,0.0001).MAP DNA wasidentified
in 17% of 143 patients receiving mesalamine and 6% of 16 receiving sulfasalazine. None of the IBD patients receiving
methotrexate (n=9), 6-MP (n=3), ciprofloxacin (n=5) or TacrolimusH (n=3) had MAP DNA detectable in their blood.
Discussion: We found a disquietingly large percentage of healthy individuals have MAP DNA in their blood, the significance
of which remains to be determined. Counter-intuitively, the incidence of MAP DNA was significantly lower in patients with
IBD. Agents with the most potent in vitro antiMAP activity were associated with clearance of blood MAP DNA. We posit that
the use antiMAP antibiotics was responsible for the decreased prevalence of MAP DNA in patients with IBD.
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Introduction
In humans, mycobacteria often colonize without causing overt
disease. In India 5% (equivalent to ,65 million) of the population
shed M. leprae DNA in their nasal secretions [1], although
,400,000 have clinical leprosy. [2] Similarly, the number of
individuals who have ‘‘latent’’ tuberculosis (30% of humankind) far
exceeds the number with clinically evident tuberculosis. [3,4]
M. avium subspecies paratuberculosis (MAP) causes a chronic
wasting enteritis in ruminants called Johne’s disease [5] that is
highly evocative of Crohn’s disease (CD). [6] Prevailing medical
dogma [7] considers that MAP is not zoonotic. [8] Yet it is of great
concern that humans worldwide are continually exposed to viable
MAP. MAP has been cultured from USA chlorinated potable
municipal water [9], pasteurized milk in the USA [10], and
Europe [11] [12], breast milk of mothers with CD [13] and from
the blood of patients with inflammatory bowel disease (IBD). [14]
Intriguingly, although Koch’s postulates [15] may already have
been met for MAP and CD [16] they have still not been met for
M. leprae and leprosy. [17]
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acknowledged as a human pathogen is that, unknowingly, the
medical profession has been treating MAP since 1942, when
sulfasalazine was introduced. [18] Until recently, it was unrecog-
nized that the ‘‘anti-inflammatory’’ 5 amino salicylic acid (5-ASA)
[19] and the ‘‘immune modulators’’ methotrexate [20], azathio-
prine [21] and its metabolite 6 mercapto-purine (6-MP) [20], [21]
are antiMAP antibiotics. We concluded that all antecedent studies
evaluating the potential zoonotic character of MAP need to be
reevaluated, as their control groups were not placebo. [19],[20]
We hypothesized that MAP may asymptomatically colonize
apparently healthy individuals. We further hypothesized that the
unwitting use of antiMAP antibiotics may be associated with a
decrease in the incidence of MAP in patients with IBD. Accordingly,
we evaluated the blood of healthy individuals and IBD patients
treated with antiMAP agents for the presence of MAP DNA.
Methods
The Ethics Committee from each institution approved this
study. Every participant signed an Informed Consent form that
was in compliance with all relevant national and European Union
regulations. There were no therapeutic interventions or alterations
in the concurrent therapy, or initiation of therapy, as a
consequence of participation.
The Control group comprised 100 subjects. The majority were
healthy blood donors (HBD) recruited from a regional Basque
Country Blood Bank. They had met all European Union
requirements for allogenic blood donation, and each denied
major infections or concomitant active disease. None gave any
history of gastrointestinal disease. The remainder of the Controls
were healthy laboratory workers from the same region.
The IBD group consisted of 246 subjects recruited from three
hospitals in the Basque Country in Northern Spain; The Quiro ´n
Donostia Clinic in Gipuzkoa (65), the Hospital de Txagorritxu in
Araba (81), and the Hospital de Galdakao in Bizkaia (100) The
clinical diagnosis of IBD had been predetermined by each treating
physician. Patients were stratified into Crohn’s disease, (CD),
ulcerative colitis (UC) or Indeterminate Colitis (IC) by clinical
histories and routine endoscopic, histological, and radiographic
criteria. Current disease status and concurrent treatment were
documented on a standardized eight item, 54 choice questionnaire
that was completed by each patient with the physician’s help.
Blood sampling
Three 4 mL whole blood tubes were obtained from each subject
(two sterile EDTA and one heparin-lithium VacutainerH tubes
(BD)). All blood samples were coded to conceal the patient’s
identity and diagnosis to laboratory workers. All samples were
processed within 4 hours after extraction in a class II bio-safety
cabinet.
Nested PCR
Genomic DNA was extracted from buffy coat cells. Briefly, one
volume blood was incubated with one volume 155 mM ammo-
nium chloride for 20 minutes to lyse the red blood cells. The tube
was centrifuged (10 mins. 2006g) the cell pellet washed twice with
PBS, recentrifuged (10 mins. 2006g). DNA was extracted and
purified (QIAamp DNA Blood Mini Kit (QIAGEN GmbH,
Hilden, Germany) and stored at 220uC until amplified.
Nested PCR was used to amplify IS900 as described. [14] In
brief, the first round primers (P90 and P91) amplify a 398 bp
fragment and the second set (AV1 and AV2) identify a 298 bp
fragment. For the first round, 10 ml of genomic DNA were added
to 40 ml of PCR buffer mixture. The PCR buffer mixture consisted
of 5 mM MgCl2, 0.2 mM dNTP, 6% DMSO, 2 mM primers and
2.5 U of Taq Polymerase (Invitrogen Ltd., Paisley, UK). In the
second round, all conditions were the same except that 5 ml of the
PCR product from the first round were used as DNA template.
PCR cycling conditions were: 95uC for 5 min, 34 cycles of: 95uC
for 1 min, 58uC for 1.5 min, 72uC for 1.5 min, with a final
extension phase of 10 min at 72uC. Amplification products were
separated using 2% agarose gel electrophoresis (150 volts;
50 mins). The positive MAP control was ATCC 19698 DNA
and the negative controls were distilled water, identically processed
with the clinical samples. A band co-migrating with the ATCC
19698 DNA at the predicted amplicon size of 298-bp was
considered positive.
The identity of the amplified 298 bp amplicon was confirmed
from two positive healthy controls and 2 IBD patients. Bands were
excised, extracted, purified (GFX PCR DNA and Gel Band
purification kit. Amersham Biosciences, Buckinghamshire, UK)
and commercially sequenced (Centro Superior de Investigaciones
Cientı ´ficas, Madrid, Spain). The sequence identity of the final
298 bp. amplicon was compared with Genebank accession
X16293 sequence for MAP IS900 using BLAST (NLM) and
sequence alignment analyses.
Contamination Avoidance Procedures
Stringent controls were adopted to minimize the possibility of
contamination. These include using a Level II Bio-safety hood to
process buffy coat for DNA extraction and using separate
uniforms, rooms, pipettes and thermocyclers for the primary and
the secondary rounds of PCR amplification.
Statistical Analyses
Comparisons of MAP DNA in blood frequencies for overall
IBD, IBD type, lesion location and type of treatment were made
using the Fisher’s exact test (SAS Institute Inc., Cary, NC 27513,
USA). Treatments were grouped by chemical structure or
presumed mechanism of action in three categories: anti-inflam-
matories or salycilic acid derivatives (SAD) (mesalamine and
sulfasalazine), immuno-modulators (azathioprine, 6-mercaptopu-
rine, methotrexate and TacrolimusH) and conventional antibiotics
(metronidazol and ciprofloxacin). Statistical significance was
accepted at p,0.05.
Results
Of the 100 Controls in this study, 90 were healthy human blood
donors and 10 healthy laboratory workers. The majority of IBD
subjects (54%; 132/246) had CD, 42% (103/246) had UC and 3%
(8/246) had IC. As a group the CD were the youngest, and IC the
oldest (Table 1). When anatomical location of maximal pathology
was reported, a minority (5%; 6/116) of CD subjects had disease
confined to the colon (Data not presented). Among subjects with
UC, a minority (42%; 38/92) had ulcerative proctitis (Data not
presented).
The PCR data (Figure 1) shows bands that co-migrate with the
positive control at the predicted amplicon size of 298 bp. The
sequenced DNA of the representative sample bands from each
clinical subset (Controls and IBD) showed .99% identity in all
cases with the Genebank accession X16293 sequence for MAP
IS900 (Data not presented).
Forty seven % (47/100) of the controls [47% (42/90) blood
donors and 50% (5/10) healthy laboratory workers] had a band
with the predicted 298 bp amplicon (Figures 1 & 2). In contrast,
16% (40/246) IBD patients had the 298 bp amplicon (p,0.0001
Treatment and MAP DNA in IBD
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differences when stratified by IBD diagnosis or location of
maximal pathology (Data not presented).
When comparing the prevalence of MAP DNA in each group of
drugs to the Controls, conventional anti-inflammatories
(p,0.0001), immuno-modulators (p,0.0001) and antibiotics
(p=0.0293) were significantly less likely to have MAP DNA in
their blood. For IBD patients receiving ‘‘No medications,’’ MAP
DNA prevalence was slightly higher (22% compared to 15% for all
IBD subjects combined). However, all IBD subsets were
significantly lower than the non-IBD control group. (Figure 2
Right hand columns).
Finally, within each chemical group or class of agents, we
evaluated individual medications. As a caveat, although these data
were collected prospectively, the analysis is post hoc and the
numbers are small.
The SAD ‘‘Anti-inflammatories’’ were sulfasalazine and mesa-
lamine. 17% receiving mesalamine (103 on mesalamine/143 not
on mesalamine) were MAP DNA positive. Among those receiving
sulfasalazine, 6% (16 on sulfasalazine/230 not on sulfasalazine)
were MAP DNA positive (Figure 3).
The ‘‘Immuno-modulators’’ prescribed were azathioprine, its
metabolite 6-MP, methotrexate and TacrolimusH. With azathio-
prine 18% were MAP DNA positive, similar to controls (50 on
azathioprine/196 not on azathioprine). In contrast, no MAP DNA
was detected when either 6-MP (3 on 6-MP/ 243 not on 6-MP),
methotrexate (9 on methotrexate; 237 not on methotrexate) or
Table 1. Classification: Crohn’s disease (CD), Ulcerative Colitis
(UC), Indeterminate Colitis (IC), & Controls (Healthy Blood
Donors and laboratory workers).
CD UC IC Controls
N 132 103 8 100
Age (years) 38.7 44.5 51.1 37.7
Sex male 58 47 4 57
Female 74 56 4 42
Duration of disease (years) 12.3 11.8 16.1 -
Disease Activity
Active 22 16 2 -
Inactive 107 87 6 -
Medications*
Salicylic acid derivatives 81 68 6 -
Anti-metabolites 41 20 1 -
Steroids 24 17 1 -
Antibiotics 11 4 1 -
Infliximab 10 2 1 -
No treatment 16 18 2 -
Anatomical Location of Maximal Disease
Colon 6 54 2 -
Ileum 103 0 1 -
Rectum 2 38 3 -
Upper digestive tract 5 0 0 -
IBD type and sex were not recorded for 3 subjects. Affected area not reported
for 30 patients. Disease activity was not recorded for 6 patients (3 treated and 3
not treated). *Multiple IBD patients were on poly-pharmaceutical therapy.
doi:10.1371/journal.pone.0002537.t001
Figure 1. Nested PCR detection of MAP DNA from peripheral
blood samples. Shown are representative samples of IBD patients and
Controls. M=molecular weight marker, lane A=negative control of first
round of PCR, lane B=negative control of second round of PCR, + =
DNA from MAP strain ATCC 19698.
doi:10.1371/journal.pone.0002537.g001
Figure 2. Shown is a bar graph of the % of 100 control subjects
who were MAP DNA positive (first column) and all 246 patients
who had IBD (second column). We next stratify IBD patients by the
class of medication that they were taking. ‘‘SAD’’=salicylic acid
derivatives. ‘‘Anti-metabolites’’ were 6-MP and its precursor azathio-
prine, methotrexate and the ‘‘immuno-suppressive’’ TacrolimusH. The
conventionally accepted antibiotics used in this study were ciproflox-
acin and metronidazole. The % MAP DNA positive are shown on the
ordinate. The total number of 270 is greater than the number of IBD
subjects (246) because some individuals were getting multiple
medications and some (37) were receiving no medications at all. All
IBD patients, whether combined or sub-stratified are significantly
different from the non-IBD controls.
doi:10.1371/journal.pone.0002537.g002
Figure 3. Shown is a post hoc analysis of the 159 IBD patients
who were receiving salicylic acid derivatives. The control group
comprises all IBD patients who were NOT receiving the agent identified.
MesalamineH is a proprietary name for 5-ASA. Sulfasalazine is a
conjugate of 5-ASA and the antibiotic sulfapyridine. Although only 16
patients were taking sulfasalazine, the incidence of MAP DNA is
significantly less than in the IBD group as a whole.
doi:10.1371/journal.pone.0002537.g003
Treatment and MAP DNA in IBD
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(Figure 4).
The conventional antibiotics prescribed were metronidazole
and ciprofloxacin. Twenty five per cent of patients receiving
metronidazole were MAP DNA positive (12 on metronidazole;
234 not on metronidazole). In contrast, none of the patients on
ciprofloxacin (5 on ciprofloxacin; 241 not on ciprofloxacin) were
MAP DNA positive (Figure 5).
Steroid therapy had no effect on the presence of MAP DNA
(16%) when combined (any steroid n=44/no steroids n=202) or
individual steroids were studied (Figure 6). ‘‘Disease Activity’’ data
were available for 98% (240/246) of IBD patients. There was no
difference in the presence or absence of MAP DNA when analysed
according to disease activity and/or concomitant medication
usage at the time of phlebotomy (Figure 7).
Discussion
The presence of MAP DNA does not address potential MAP
viability, anymore than the presence of M. leprae DNA in nasal
secretions [1] determines possible M. leprae infectivity. Neverthe-
less, our data shows a disquietingly high 47% of healthy
individuals have MAP DNA in their blood. These data thus
corroborate and extend a prior study showing 20% MAP DNA
positivity in non-IBD subjects. [14] We conclude that the possible
viability of MAP in blood, that may have allogenic use, should be
expeditiously clarified.
‘‘Anti-inflammatory’’ (5-ASA), ‘‘immuno-modulatory’’ agents
(azathioprine its metabolite 6-MP and methotrexate) and the
‘‘immuno-suppressive’’ agent TacrolimusH are used to treat IBD
and multiple ‘‘inflammatory’’ and ‘‘autoimmune’’ diseases. This is
despite the fact that the ‘‘mechanism of action (of 5-ASA) in the
therapy of IBD is unclear’’ [22] and all are used simply because of
empirical efficacy. In this study, we show that 5-ASA decreases the
incidence of MAP DNA from the blood of patients with IBD. We
additionally show that the ‘‘immuno-modulators’’ 6-MP and
Figure 4. Shown is a post hoc analysis of the 62 IBD patients
who were receiving ‘‘anti-metabolites’’, agents recently shown
to be potent antiMAP antibiotics. [20] [21] The control group
comprises all IBD patients who were NOT receiving the agent identified.
The majority were receiving the precursor of 6-MP, azathioprine. No
MAP DNA is found when 6-MP, methotrexate and Tacrolimus are used.
doi:10.1371/journal.pone.0002537.g004
Figure 5. Shown is a post hoc analysis of the 16 IBD patients
who were receiving conventional antibiotics, ciprofloxacin and
metronidazole. There was no MAP DNA detected in the small number
of patients taking ciprofloxacin.
doi:10.1371/journal.pone.0002537.g005
Figure 6. Shown are the data for the individual steroids used;
prednisone, budesonide and triamcinolone. There are no
significant differences noted.
doi:10.1371/journal.pone.0002537.g006
Figure 7. Shown is a comparison of the percentage of IBD
patients who reported, at the time of phlebotomy to have
‘‘Active’’ (#=40) or ‘‘Inactive disease’’ (#=200). For the
remaining 6 patients ‘‘Disease Activity’’ data were not provided on
their questionnaire. In this post hoc analysis, with group sizes that are
not comparable, there is no difference in the presence or absence of
MAP DNA among the groups. Our questionnaire did NOT obtain
information on medications that had been used PRIOR to the day of
phlebotomy.
doi:10.1371/journal.pone.0002537.g007
Treatment and MAP DNA in IBD
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clear MAP DNA.
We found that all of our IBD subset groups, including those on
‘‘no active medications’’, had a lower incidence of MAP DNA
than the non-IBD control group (Figure 2). The most plausible
explanation for the fact that IBD patients on no medication have a
lower incidence of MAP DNA than the non-IBD controls is that
our questionnaire did not request a history of medications that had
been used by the IBD patients prior to the day of phlebotomy.
Thus, those patients who were reported as being ‘‘On no
medications’’ at the time of phlebotomy may well have been
exposed to antiMAP agents in the past. (Figures 2 & 7).
Because of small numbers, our post hoc analyses should be
considered as tentative. Nevertheless, our observations are
compatible with the thesis that 5-ASA [19], azathioprine [21], 6-
MP [20] [21] and methotrexate [20] are acting as antiMAP
antibiotics. They also corroborate our in vitro data that 5-ASA [19]
is a far less potent antiMAP antibiotic than are 6-MP and
methotrexate. [20]
Tacrolimus [23] is an ‘‘immuno-suppressive’’ medication most
used to prevent organ transplant rejection [24] and morerecently in
the therapy of IBD. [25] It is of considerable interest that
Tacrolimus is from the macrolide antibiotic family of medications
[23], amongst the most potent anti M. avium antibiotic families. [26]
Ciprofloxacin clears MAP DNA. This is an antibiotic, which
has shown an activity against different strains of MAP ‘‘in vitro.’’
[27] In contrast, metronidazole an alternative antibiotic used in
this study does not clear MAP DNA. Our data suggest that
ciprofloxacin is a more effective antiMAP antibiotic than is
metronidazole. These initial observations provide insights that
should be of use when determining which agents should be
evaluated when designing future, pivotal, clinical trials.
The use of the TNF alpha antagonist InfliximabH is associated
with reactivation of latent tuberculosis and requires concomitant
use of anti-tuberculosis prophylaxis. We find only 9% (2/13) of our
patients treated with infliximab are MAP DNA positive. Our
observations are therefore at variance with the 80% (4/5) culture
of MAP from the blood of patients who were receiving infliximab
in a prior study. [14] The most plausible explanation for these
discrepant observations are the potent antiMAP agents that were
concomitantly used in our patients. (Table 2). Prudence suggests
that, until the potential MAP zoonosis conundrum is finally
resolved, any individual being treated with TNF alpha antagonists,
for any disease, should continue to receive antiMAP agents such as
5-ASA, sulfasalazine, methotrexate, 6-MP, ciprofloxacin, Tacro-
limus or another macrolide antibiotics.
When steroids are used to treat the inflammatory reaction in
tuberculosis, anti-tuberculosis medications are always co-adminis-
tered. [28,29] MAP has been cultured from 60% (3/5) IBD
patients receiving steroids. [14] However, our data do not show an
increase in the incidence of MAP DNA when steroids are used.
Again, the most reasonable explanation is the potent antiMAP
agents that were co-administered in our patients being given
steroids. We conclude that caution suggests that whenever steroids
are used in the therapy of IBD, concomitant antiMAP agents
should always be used.
If MAP zoonosis is accepted, MAP antibiotic susceptibility
studies will need to be performed. However, few laboratories can
successfully culture the cell wall deficient form of MAP that exists
in humans [14,30,31], a process that may take up to 18 months.
[30] Nucleic acid based methods, to more rapidly determine the
presence of MAP RNA (indicating viability) [9], potential
infectivity [32] [33] and antibiotic susceptibility [34] may need
to be developed. Our data suggest that until such nucleic acid
based methodologies are available, identifying MAP DNA prior
to, and its clearance following initiation of antiMAP therapy, may
provide the most readily available practicable surrogate to in vitro
MAP antibiotic susceptibility information.
Author Contributions
Conceived and designed the experiments: RG RJ JG IO. Performed the
experiments: NE JG AP MG IS RC AI. Analyzed the data: RJ.
Contributed reagents/materials/analysis tools: NE AP MG JC AT FG
RC AI. Wrote the paper: RG.
References
1. Ramaprasad P, Fernando A, Madhale S, Rao JR, Edward VK, et al. (1997)
Transmission and protection in leprosy: indications of the role of mucosal
immunity. Lepr Rev 68: 301–315.
2. Britton WJ, Lockwood DN (2004) Leprosy. Lancet 363: 1209–1219.
3. 2003 WHO annual report on global TB control–summary. Wkly Epidemiol Rec
78: 122–128.
4. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The
growing burden of tuberculosis: global trends and interactions with the HIV
epidemic. Arch Intern Med 163: 1009–1021.
5. Johne HA, Frothingham L (1895) Ein eigenthumlicher fall von tuberculose beim
rind ( A particular case of tuberculosis in a cow). Dtsch Zeitschr Tiermed, Vergl
Pathol 21: 438–454.
6. Dalziel TK (1913) Chronic intestinal enteritis. British Medical Journal ii:
1068–1070.
7. Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, et al. (2007) Two-year
combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine
for Crohn’s disease. Gastroenterology 132: 2313–2319.
8. Greenstein RJ, Collins MT (2004) Emerging pathogens: is Mycobacterium
avium subspecies paratuberculosis zoonotic? Lancet 364: 396–397.
9. Mishina D, Katsel P, Brown ST, Gilberts EC, Greenstein RJ (1996) On
the etiology of Crohn disease. Proc Natl Acad Sci U S A 93: 9816–
9820.
10. Ellingson JL, Anderson JL, Koziczkowski JJ, Radcliff RP, Sloan SJ, et al. (2005)
Detection of viable Mycobacterium avium subsp. paratuberculosis in retail
Table 2. MAP DNA in the blood of IBD patients who were receiving InfliximabH (n=13).
MAP DNA Clearance Meds Azathioprine Steroids (Prednisolone) No other therapy
%( #/#)%( #/#)% ( #/#)% ( #/#)% ( #/#)
Negative 85 11/13 55 6/11 36 4/11 9 1/11 9 1/11
Positive 15 2/13 0 0/2 100 2/2 50 1/2 0 0/2
Totals 100 13/13 46 6/13 46 6/13 15 2/13 8 1/13
‘‘Clearance medications’’ are agents that, in this study, were associated with the absence of MAP DNA in the blood of IBD patient’s samples. These were: methotrexate,
6-MP, ciprofloxacin, and TacrolimusH.
doi:10.1371/journal.pone.0002537.t002
Treatment and MAP DNA in IBD
PLoS ONE | www.plosone.org 5 July 2008 | Volume 3 | Issue 7 | e2537pasteurized whole milk by two culture methods and PCR. J Food Prot 68:
966–972.
11. Grant IR, Hitchings EI, McCartney A, Ferguson F, Rowe MT (2002) Effect of
Commercial-Scale High-Temperature,S h o r t - T i m eP a s t e u r i z a t i o no nt h e
Viability of Mycobacterium paratuberculosis in Naturally Infected Cows’ Milk.
Appl Environ Microbiol 68: 602–607.
12. Ayele WY, Svastova P, Roubal P, Bartos M, Pavlik I (2005) Mycobacterium
avium subspecies paratuberculosis cultured from locally and commercially
pasteurized cow’s milk in the Czech Republic. Appl Environ Microbiol 71:
1210–1214.
13. Naser SA, Schwartz D, Shafran I (2000) Isolation of Mycobacterium avium
subsp paratuberculosis from breast milk of Crohn’s disease patients.
Am J Gastroenterol 95: 1094–1095.
14. Naser SA, Ghobrial G, Romero C, Valentine JF (2004) Culture of Mycobacterium
avium subspecies paratuberculosis from the blood of patients with Crohn’s disease.
Lancet 364: 1039–1044.
15. Koch R (1882) Die Aetilogie der Tuberculose. Berl, klin, Wschr 19: 221–230.
16. Greenstein RJ (2003) Is Crohn’s disease caused by a mycobacterium?
Comparisons with leprosy, tuberculosis, and Johne’s disease. Lancet Infect Dis
3: 507–514.
17. Stewart-Tull DES (1982) Mycobacterium leprae - The bacteriologist’s enigma. In:
Ratledge C, Stanford J, eds (1982) The Biology of the Mycobacteria, Volume 1:
Physiology, Identification, and Classification. 1 ed. New york: Academic Press.
pp 273–307.
18. Svartz N (1942) Salazopyrin, a new sulfanilamide preparation. A. Therapeutic
Results in Rheumatic Polyarthritis. B. Therapeutic Results in Ulcerative Colitis.
C. Toxic Manifestations in Treatment with Sulfanilamide Preparations. Acta
Medica Scandinavica 110: 577–598.
19. Greenstein RJ, Su L, Shahidi A, Brown ST (2007) On the Action of 5-Amino-
Salicylic Acid and Sulfapyridine on M. avium including Subspecies paratuber-
culosis. PLoS ONE 2: e516.
20. Greenstein RJ, Su L, Haroutunian V, Shahidi A, Brown ST (2007) On the
Action of Methotrexate and 6-Mercaptopurine on M. avium Subspecies
paratuberculosis. PLoS ONE 2: e161.
21. Shin SJ, Collins MT (2008) Thiopurine drugs (azathioprine and 6-mercapto-
purine) inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob
Agents Chemother 52: 418–426.
22. Berardi RR (1996) Inflammatory Bowel Disease. In: Herfindal ET, Gourley DR,
eds (1996) Textbook of Therapeutics Drugs and Disease Management.
Baltimore: Williams and Wilkins. pp 483–502.
23. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, et al. (1987) FK-
506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation,
isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo)
40: 1249–1255.
24. Spencer CM, Goa KL, Gillis JC (1997) Tacrolimus. An update of its
pharmacology and clinical efficacy in the management of organ transplantation.
Drugs 54: 925–975.
25. Ng SC, Arebi N, Kamm MA (2007) Medium-term results of oral tacrolimus
treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 13:
129–134.
26. Barrow WW, Wright EL, Goh KS, Rastogi N (1993) Activities of fluoroquin-
olone, macrolide, and aminoglycoside drugs combined with inhibitors of
glycosylation and fatty acid and peptide biosynthesis against Mycobacterium
avium. Antimicrob Agents Chemother 37: 652–661.
27. Zanetti S, Molicotti P, Cannas S, Ortu S, Ahmed N, et al. (2006) ‘‘In vitro’’
activities of antimycobacterial agents against Mycobacterium avium subsp.
paratuberculosis linked to Crohn’s disease and paratuberculosis. Ann Clin
Microbiol Antimicrob 5: 27.
28. Prasad K, Volmink J, Menon GR (2000) Steroids for treating tuberculous
meningitis. Cochrane Database Syst Rev. pp CD002244.
29. Farinha NJ, Razali KA, Holzel H, Morgan G, Novelli VM (2000) Tuberculosis
of the central nervous system in children: a 20-year survey. J Infect 41: 61–68.
30. Chiodini RJ, Van Kruiningen HJ, Merkal RS, Thayer Jr. WR, Coutu JA (1984)
Characteristics of an unclassified Mycobacterium species isolated from patients with
Crohn’s disease. J Clin Microbiol 20: 966–971.
31. Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, et al. (2003)
Detection and verification of Mycobacterium avium subsp. paratuberculosis in
fresh ileocolonic mucosal biopsy specimens from individuals with and without
Crohn’s disease. J Clin Microbiol 41: 2915–2923.
32. Ivnitski D, O’Neil DJ, Gattuso A, Schlicht R, Calidonna M, et al. (2003) Nucleic
acid approaches for detection and identification of biological warfare and
infectious disease agents. Biotechniques 35: 862–869.
33. Sampath R, Hall TA, Massire C, Li F, Blyn LB, et al. (2007) Rapid identification
of emerging infectious agents using PCR and electrospray ionization mass
spectrometry. Ann N Y Acad Sci 1102: 109–120.
34. Lindler LE, Fan W (2003) Development of a 59 nuclease assay to detect
ciprofloxacin resistant isolates of the biowarfare agent Yersinia pestis. Mol Cell
Probes 17: 41–47.
Treatment and MAP DNA in IBD
PLoS ONE | www.plosone.org 6 July 2008 | Volume 3 | Issue 7 | e2537